Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 76

1.

Comparative efficacy between atorvastatin and rosuvastatin in the prevention of cardiovascular disease recurrence.

Perez-Calahorra S, Laclaustra M, Marco-Benedi V, Pinto X, Sanchez-Hernandez RM, Plana N, Ortega E, Fuentes F, Civeira F.

Lipids Health Dis. 2019 Dec 11;18(1):216. doi: 10.1186/s12944-019-1153-x.

2.

Derivation and validation of SIDIAP-FHP score: A new risk model predicting cardiovascular disease in familial hypercholesterolemia phenotype.

Ramos R, Masana L, Comas-Cufí M, García-Gil M, Martí-Lluch R, Ponjoan A, Plana N, Alves-Cabratosa L, Marrugat J, Elosua R, Dégano IR, Gomez-Marcos MA, Zamora A.

Atherosclerosis. 2020 Jan;292:42-51. doi: 10.1016/j.atherosclerosis.2019.10.016. Epub 2019 Oct 30.

PMID:
31759248
3.

The Circulating GRP78/BiP Is a Marker of Metabolic Diseases and Atherosclerosis: Bringing Endoplasmic Reticulum Stress into the Clinical Scenario.

Girona J, Rodríguez-Borjabad C, Ibarretxe D, Vallvé JC, Ferré R, Heras M, Rodríguez-Calvo R, Guaita-Esteruelas S, Martínez-Micaelo N, Plana N, Masana L.

J Clin Med. 2019 Oct 26;8(11). pii: E1793. doi: 10.3390/jcm8111793.

4.

Clinical and genetic differences between heterozygous familial hypercholesterolemia patients with and without type 2 diabetes.

Climent E, Pérez-Calahorra S, Benaiges D, Pintó X, Suárez-Tembra M, Plana N, Sánchez-Hernández RM, Valdivielso P, Ascaso JF, Pedro-Botet J.

Rev Esp Cardiol (Engl Ed). 2019 Oct 28. pii: S1885-5857(19)30262-2. doi: 10.1016/j.rec.2019.09.001. [Epub ahead of print] English, Spanish.

PMID:
31672559
5.

Incidence of Cardiovascular Disease in Patients with Familial Hypercholesterolemia Phenotype: Analysis of 5 Years Follow-Up of Real-World Data from More than 1.5 Million Patients.

Masana L, Zamora A, Plana N, Comas-Cufí M, Garcia-Gil M, Martí-Lluch R, Ponjoan A, Alves-Cabratosa L, Elosua R, Marrugat J, Dégano IR, Ramos R.

J Clin Med. 2019 Jul 23;8(7). pii: E1080. doi: 10.3390/jcm8071080.

6.

Update of therapeutic planning tables oriented towards obtaining therapeutic objectives.

Masana L, Plana N.

Clin Investig Arterioscler. 2019 Nov - Dec;31(6):271-277. doi: 10.1016/j.arteri.2019.04.005. Epub 2019 Jul 9. English, Spanish.

PMID:
31296342
7.

HDL Triglycerides: A New Marker of Metabolic and Cardiovascular Risk.

Girona J, Amigó N, Ibarretxe D, Plana N, Rodríguez-Borjabad C, Heras M, Ferré R, Gil M, Correig X, Masana L.

Int J Mol Sci. 2019 Jun 27;20(13). pii: E3151. doi: 10.3390/ijms20133151.

8.

Toward a new clinical classification of patients with familial hypercholesterolemia: One perspective from Spain.

Masana L, Ibarretxe D, Rodríguez-Borjabad C, Plana N, Valdivielso P, Pedro-Botet J, Civeira F, López-Miranda J, Guijarro C, Mostaza J, Pintó X; Expert group from the Spanish Arteriosclerosis Society.

Atherosclerosis. 2019 Aug;287:89-92. doi: 10.1016/j.atherosclerosis.2019.06.905. Epub 2019 Jun 20. Review.

PMID:
31238171
9.

Standards for global cardiovascular risk management arteriosclerosis.

Mostaza JM, Pintó X, Armario P, Masana L, Ascaso JF, Valdivielso P; en nombre de la Sociedad Española de Arteriosclerosis; Miembros de la Sociedad Española de Arteriosclerosis.

Clin Investig Arterioscler. 2019 Jul;31 Suppl 1:1-43. doi: 10.1016/j.arteri.2019.03.004. Epub 2019 Apr 11. English, Spanish.

10.

Estimated Percentage of Patients With Stable Coronary Heart Disease Candidates for PCSK9 Inhibitors. Response.

Zamora A, Masana L, Plana N, Ramos R.

Rev Esp Cardiol (Engl Ed). 2019 Jun;72(6):519-520. doi: 10.1016/j.rec.2018.12.009. Epub 2019 Mar 28. English, Spanish. No abstract available.

PMID:
30930255
11.

Effect of lipid-lowering treatment in cardiovascular disease prevalence in familial hypercholesterolemia.

Perez-Calahorra S, Laclaustra M, Marco-Benedí V, Lamiquiz-Moneo I, Pedro-Botet J, Plana N, Sanchez-Hernandez RM, Amor AJ, Almagro F, Fuentes F, Suarez-Tembra M, Civeira F; Dyslipemia Registry of Spanish Arteriosclerosis Society.

Atherosclerosis. 2019 May;284:245-252. doi: 10.1016/j.atherosclerosis.2019.02.003. Epub 2019 Feb 12.

PMID:
30827715
12.

Detecting familial hypercholesterolemia earlier in life by actively searching for affected children:The DECOPIN project.

Ibarretxe D, Rodríguez-Borjabad C, Feliu A, Bilbao JÁ, Masana L, Plana N.

Atherosclerosis. 2018 Nov;278:210-216. doi: 10.1016/j.atherosclerosis.2018.09.039. Epub 2018 Oct 1.

PMID:
30312929
13.

Autosomal dominant hypercholesterolemia in Catalonia: Correspondence between clinical-biochemical and genetic diagnostics in 967 patients studied in a multicenter clinical setting.

Martín-Campos JM, Plana N, Figueras R, Ibarretxe D, Caixàs A, Esteve E, Pérez A, Bueno M, Mauri M, Roig R, Martínez S, Pintó X, Masana L, Julve J, Blanco-Vaca F; Xarxa d’Unitats de Lípids i Arteriosclerosi (XULA).

J Clin Lipidol. 2018 Nov - Dec;12(6):1452-1462. doi: 10.1016/j.jacl.2018.09.002. Epub 2018 Sep 7.

PMID:
30293936
14.

Number of Patients Eligible for PCSK9 Inhibitors Based on Real-world Data From 2.5 Million Patients.

Zamora A, Masana L, Comas-Cufi M, Plana N, Vila À, García-Gil M, Alves-Cabratosa L, Elosua R, Marrugat J, Ramos R.

Rev Esp Cardiol (Engl Ed). 2018 Dec;71(12):1010-1017. doi: 10.1016/j.rec.2018.03.003. Epub 2018 Mar 30. English, Spanish.

PMID:
29606363
15.

Lipid and lipoprotein parameters for detection of familial hypercholesterolemia in childhood. The DECOPIN Project.

Plana N, Rodríguez-Borjabad C, Ibarretxe D, Ferré R, Feliu A, Caselles A, Masana L; en representación del proyecto DECOPIN.

Clin Investig Arterioscler. 2018 Jul - Aug;30(4):170-178. doi: 10.1016/j.arteri.2017.12.003. Epub 2018 Mar 27. English, Spanish.

PMID:
29602595
16.

Lipoprotein profile assessed by 2D-1H-NMR and subclinical atherosclerosis in children with familial hypercholesterolaemia.

Rodríguez-Borjabad C, Ibarretxe D, Girona J, Ferré R, Feliu A, Amigó N, Guijarro E, Masana L, Plana N; DECOPIN Group.

Atherosclerosis. 2018 Mar;270:117-122. doi: 10.1016/j.atherosclerosis.2018.01.040. Epub 2018 Jan 31.

PMID:
29407879
17.

Clinical and pathophysiological evidence supporting the safety of extremely low LDL levels-The zero-LDL hypothesis.

Masana L, Girona J, Ibarretxe D, Rodríguez-Calvo R, Rosales R, Vallvé JC, Rodríguez-Borjabad C, Guardiola M, Rodríguez M, Guaita-Esteruelas S, Oliva I, Martínez-Micaelo N, Heras M, Ferré R, Ribalta J, Plana N.

J Clin Lipidol. 2018 Mar - Apr;12(2):292-299.e3. doi: 10.1016/j.jacl.2017.12.018. Epub 2018 Jan 8. Review.

PMID:
29398429
18.

Altered HDL Remodeling and Functionality in Familial Hypercholesterolemia.

Cedó L, Plana N, Metso J, Lee-Rueckert M, Sanchez-Quesada JL, Kovanen PT, Jauhiainen M, Masana L, Escolà-Gil JC, Blanco-Vaca F.

J Am Coll Cardiol. 2018 Jan 30;71(4):466-468. doi: 10.1016/j.jacc.2017.11.035. No abstract available.

19.

Plasma inducible degrader of the LDLR, soluble low-density lipoprotein receptor, and proprotein convertase subtilisin/kexin type 9 levels as potential biomarkers of familial hypercholesterolemia in children.

Girona J, Rodríguez-Borjabad C, Ibarretxe D, Heras M, Amigo N, Feliu A, Masana L, Plana N; DECOPIN Group.

J Clin Lipidol. 2018 Jan - Feb;12(1):211-218. doi: 10.1016/j.jacl.2017.10.003. Epub 2017 Oct 12.

PMID:
29102496
20.

National Dyslipidemia Registry of the Spanish Arteriosclerosis Society: Current status.

Pérez-Calahorra S, Sánchez-Hernández RM, Plana N, Valdivielso P, Civeira F.

Clin Investig Arterioscler. 2017 Nov - Dec;29(6):248-253. doi: 10.1016/j.arteri.2017.09.001. Epub 2017 Nov 2. English, Spanish.

PMID:
29102473

Supplemental Content

Loading ...
Support Center